New oral anticoagulants and their reversal agents

Atrial fibrillation's increasing prevalence posed challenges due to the need for careful management of hemorrhagic and thrombotic risks with traditional vitamin K antagonists. The introduction of new oral anticoagulants (NOACs) improved patients' quality of life by eliminating the need for close monitoring and dose adjustments. Despite their superior safety profile, the issue of managing unexpected hemorrhages in patients on NOACs persisted. To address this, reversal agents like idarucizumab and andexanet-alpha were developed and approved by the FDA, enhancing the appeal of NOACs as a treatment option.